Hengrui Pharma 恒瑞医药
15 significant filings since 31 May 2026: 10 on buyback and 5 on equity incentive. The latest, on 18 Sep 2026: 恒瑞医药关于首次回购公司A股股份的公告.
自 31 May 2026 起有 15 份重大公告：buyback 10 份、equity incentive 5 份。最新一份（18 Sep 2026）：恒瑞医药关于首次回购公司A股股份的公告。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 1.37 | 1.63 |
| 7 days ago | 1.37 | 1.63 |
| 30 days ago | 1.44 | 1.69 |
| 60 days ago | 1.40 | 1.63 |
| 90 days ago | 1.40 | 1.68 |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
Consensus moved from 1.27 in Sep 2024 to 1.37 in Sep 2026 (+8.1%). 一致预期从 Sep 2024 的 1.27 变为 Sep 2026 的 1.37 (+8.1%)。 The shaded band runs from the lowest to the highest broker forecast.
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
| Last 90 days | ▲ 2 ▼ 2 = 0 | ▲ 1 ▼ 3 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
| Year | Filed | Consensus | Brokers 券商 | Reported 实际 | Surprise 偏差 |
|---|---|---|---|---|---|
| FY2022 | 22 Apr 2023 | 0.66 | 3 | 0.61 | -7.7% |
| FY2019 | 23 Mar 2020 | 1.19 | 3 | 1.00 | -16.0% |
Surprise is reported EPS against the consensus on the day before the annual report was filed. 偏差为实际每股收益与年报披露前一日一致预期之差。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 0. 惊喜幅度需公告前120天内至少3家券商预测；FY2025仅0家；FY2024仅0家。